Changes in Histaminergic System in Neuropsychiatric Disorders and the Potential Treatment Consequences

In contrast to that of other monoamine neurotransmitters, the association of the histaminergic system with neuropsychiatric disorders is not well documented. In the last two decades, several clinical studies involved in the development of drugs targeting the histaminergic system have been reported. These include the H3R-antagonist/inverse agonist, pitolisant, used for the treatment of excessive sleepiness in narcolepsy, and the H1R antagonist, doxepin, used to alleviate symptoms of insomnia. The current review summarizes reports from animal models, including genetic and neuroimaging studies, as well as human brain samples and cerebrospinal fluid measurements from clinical trials, on the possible role of the histaminergic system in neuropsychiatric disorders. These studies will potentially pave the way for novel histamine-related therapeutic strategies.

Automated summary

Compared to other monoamine neurotransmitters, the link between the histaminergic system and neuropsychiatric disorders is not well established. However, recent studies using animal models, genetic and neuroimaging approaches, and clinical trials suggest a potential role of the histaminergic system in these disorders, which may lead to the development of novel histamine-related therapeutic strategies.